1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
Head and Neck Squamous Cell Carcinoma - Epidemiology Forecast to 2030

Head and Neck Squamous Cell Carcinoma - Epidemiology Forecast to 2030

  • August 2021
  • 56 pages
  • ID: 6134077
  • Format: PDF
  • GlobalData

Summary

Table of Contents

Search Inside

Head and Neck Squamous Cell Carcinoma - Epidemiology Forecast to 2030

Summary
Head and neck cancers (HNCs) are a heterogeneous group consisting of cancers of the mouth, including the lip, tongue, gum, floor of mouth, palate, and other parts of mouth (ICD-10 code = C00-C06),; the salivary glands (ICD-10 code = C07-C08); the pharynx, including the tonsil, oropharynx, nasopharynx, pyriform fossa, hypopharynx, other mouth/pharynx (ICD-10 code = C09-C14); the nose, sinuses, and related structures (ICD-10 code = C30-C31), and the larynx (ICD-10 code = C32) (World Health Organization, 2011).HNCs usually begin in the squamous cells that line the moist mucosal surfaces of the tissues and organs of the head and neck.

It is estimated that more than 80% of all oral cavity and pharynx cancers are squamous cell carcinomas (Howlader et al., 2020; National Cancer Institute, 2021).

In the 8MM, the diagnosed incident cases of HNC are expected to increase from 279,734 cases in 2020 to 338,790 cases in 2030, at an Annual Growth Rate (AGR) of 2.11%. In 2030, urban China will have the highest number of diagnosed incident cases of HNC in the 8MM, with 141,960 diagnosed incident cases, whereas Italy will have the fewest diagnosed incident cases with 13,720 cases. In the 8MM, the five-year diagnosed prevalent cases of HNC are expected to increase from 836,755 cases in 2020 to 1,018,417 cases in 2030, at an AGR of 2.17%Epidemiologists attribute the increase in the five-year diagnosed prevalent cases and diagnosed incident cases of HNC to diagnosed incidence rate, regression trend analysis and survival rates, and population dynamics in each market.

Scope
This report provides an overview of the risk factors, comorbidities, and the global and historical trends for HNCs in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and urban China).

The report provides a 10-year epidemiological forecast of the diagnosed incident cases of HNCs. In this analysis, HNCs are grouped into the following groups -
- Cancers of the lip, oral cavity, pharynx, and larynx cancer (ICD-10 = C00-C06, C09, C12-C14, C32, and C10 [HPV-]); Oropharynx cancer (ICD-10 = C10); Nasopharynx cancer (ICD-10 = C11); Other HNC sites-salivary gland and nose, sinuses, and other related structures’ cancer (ICD-10 = C07-C08 and C30-C31).
- Each of the four groups is further segmented by risk factor (tobacco smoking history), histology distribution (squamous cell and non-squamous cell), and clinical stage at diagnosis among the squamous cell carcinomas. In addition, the diagnosed incident cases of oropharynx cancer were further segmented by risk factor (human papillomavirus infection status HPV+ and HPV-) and the diagnosed incident cases nasopharynx cancer were segmented by the risk factor of Epstein Barr virus infection (EBV+). The report provides a 10-year epidemiological forecast of the five-year diagnosed prevalent cases of each of the four groups.
- The HNC epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to Buy
The HNCs Epidemiology series will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global HNCs market.
- Quantify patient populations in the global HNCs market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups that present the best opportunities for HNCs therapeutics in each of the markets covered.
- Understand magnitude of HNCs by stage at diagnosis, risk factors, EGFR mutation, PD-L1 expression by CPS scores, and surgical and radiotherapy vs. systemic treatment.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Global Radiotherapy Market – Analysis By Procedure (External Radiation, Internal Radiation), Product, Application, By Region, By Country (2021 Edition): Market Insights and Forecast with Impact of COVID-19 (2021-2026)

  • $ 2400
  • July 2021
  • 240 pages

Executive Summary Global Radiotherapy Market was valued at USD 7987.01 Million in the year 2020. Increasing healthcare expenditure on the back of growing disposable income, rapid technological advancements ...

  • World
  • Cancer
  • Specialty Hospital
  • Industry analysis
  • Cancer Incidence
  • Health Expenditure

ref:plp2021

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on